1-5 of 5
Dario Sterker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B143: HRO761, a first-in-class, clinical stage WRN inhibitor with potent preclinical anti-tumor activity in MSIhigh models

Stephane Ferretti, Isabel Jaco, Andrea Decker, Christelle Hemmerlin, Clemens Scheufler, Cornelia Quadt, Dario Sterker, Elena Gavioli, Eloisa Jimenez Nunez, Ernesta Dammassa, Fanny Schaeffer, Genevieve Albrecht, Giorgia Clementi, Hansjoerg Martus, Jacques Hamon, Juergen Hinrichs, Laurent Laborde, Marion Dourdoigne, Michele Moschetta, Ramona Stump, Rita Andraos-Rey, Sarah Welly, Stephanie Barbe, Vincent Romanet, Markus Reschke, Ruben De Kanter, Michael Jensen, Henrik Moebitz, Marta Cortes Cros
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B143.
https://doi.org/10.1158/1535-7163.TARG-23-B143
Published: 01 December 2023
View article titled, Abstract B143: HRO761, a first-in-class, clinical stage WRN inhibitor with potent preclinical anti-tumor activity in MSI<sup>high</sup> models
Journal Articles

Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models

Saskia M. Brachmann, Andreas Weiss, Daniel A. Guthy, Kim Beyer, Johannes Voshol, Michel Maira, Anirudh Prahallad, Diana Graus Porta, Christian Schnell, Nils Ostermann, Andrea Vaupel, Marc Gerspacher, Catherine Leblanc, Dirk Erdmann, Dario Sterker, Grainne Kerr, Giovannoni Jerome, Victoria Head, Rowan Stringer, Ruben De Kanter, Kearns Jeff, Danielle Roman, Toni Widmer, Peter Wessels, Eloisa Jimenez Nunez, Richard Sedrani, Frederic Zecri, Francesco Hofmann, Jeff Engleman, Edwige Lorthiois, Simona Cotesta
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P124.
https://doi.org/10.1158/1535-7163.TARG-21-P124
Published: 01 December 2021
View article titled, Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models
Journal Articles

FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Andreas Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm, Robin A. Fairhurst, Michael Kiffe, Dario Sterker, Mario Centeleghe, Markus Wartmann, Jacqueline Kinyamu-Akunda, Heiko S. Schadt, Philippe Couttet, Armin Wolf, Youzhen Wang, Patrizia Barzaghi-Rinaudo, Masato Murakami, Audrey Kauffmann, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Pascal Furet, Jutta Blank, Francesco Hofmann, William R. Sellers, Diana Graus Porta
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2194–2206.
https://doi.org/10.1158/1535-7163.MCT-18-1291
Published: 02 December 2019
View article titled, FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Open the PDF for FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer in another window
Includes: Supplementary data
Journal Articles

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Saskia M. Brachmann, Julia Kleylein-Sohn, Swann Gaulis, Audrey Kauffmann, Marcel J.J. Blommers, Malika Kazic-Legueux, Laurent Laborde, Marc Hattenberger, Fabian Stauffer, Juliane Vaxelaire, Vincent Romanet, Chrystèle Henry, Masato Murakami, Daniel Alexander Guthy, Dario Sterker, Sebastian Bergling, Christopher Wilson, Thomas Brümmendorf, Christine Fritsch, Carlos Garcia-Echeverria, William R. Sellers, Francesco Hofmann, Sauveur-Michel Maira
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (8): 1747–1757.
https://doi.org/10.1158/1535-7163.MCT-11-1021
Published: 08 August 2012
View article titled, Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
Open the PDF for Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations in another window
Includes: Supplementary data
Journal Articles

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Matthew Burger, Mark Knapp, Dario Sterker, Christian Schnell, Daniel Guthy, Tobi Nagel, Marion Wiesmann, Saskia Brachmann, Christine Fritsch, Marion Dorsch, Patrick Chène, Kevin Shoemaker, Alain De Pover, Daniel Menezes, Georg Martiny-Baron, Doriano Fabbro, Christopher J. Wilson, Robert Schlegel, Francesco Hofmann, Carlos García-Echeverría, William R. Sellers, Charles F. Voliva
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 317–328.
https://doi.org/10.1158/1535-7163.MCT-11-0474
Published: 08 February 2012
View article titled, Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Open the PDF for Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor in another window
Includes: Supplementary data